Kairos Pharma (KAPA) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Silexion Therapeutics is the larger company by market cap ($3.1 million vs $2.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KAPA | SLXN |
|---|---|---|
| Share price | $0.8103 | $0.2146 |
| Market cap | $2.74M | $3.11M |
| 1-day change | -15.55% | -8.64% |
| EPS (TTM) | $-1.96 | $-24.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.17 | $39.40 |
| 52-week low | $0.7827 | $0.2079 |
| Distance from 52-week high | -91.16% | -99.46% |
| Analyst consensus | none | none |
| Avg. price target upside | +5947.14% | +2229.92% |
| Average volume | 613.04K | 10.05M |
| Shares outstanding | 3.39M | 14.47M |
| Employees | 1 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kairos Pharma
KAPA stock →Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
KAPA vs SLXN FAQ
Which is bigger, Kairos Pharma or Silexion Therapeutics?
Silexion Therapeutics (SLXN) is larger, with a market capitalization of $3.11M compared with $2.74M for Kairos Pharma (KAPA).
Are Kairos Pharma and Silexion Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Kairos Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for Silexion Therapeutics.